^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer

Published date:
07/27/2021
Excerpt:
we tested the ability of MHC-II expression on tumor cells, to predict immunotherapy-specific benefit in the neoadjuvant breast cancer setting. Quantitative assessment of MHC-II on tumor cells was predictive of durvalumab + NAC and pembrolizumab + NAC...Tumor-specific MHC-II has strong candidacy as a specific biomarker of anti-PD-1/L1 immunotherapy benefit when added to standard NAC in HER2-negative breast cancer.
Secondary therapy:
Chemotherapy
DOI:
10.1158/1078-0432.CCR-21-0607